Subscribe to ExpertReview

The latest research, meeting updates and CME, in your inbox.

Hong Kong · Sponsored

Safety and Immunogenicity of the BNT162b2 mRNA Covid-19 Vaccine in Patients after Allogeneic HCT or CD19-based CAR-T therapy

20 Jul 2021

Coco Chong

Share

This content is sponsored. It is intended for healthcare professionals only.

In this single centre prospective cohort study, the efficacy and toxicity of BNT162b2 vaccine were evaluated in patients who underwent haematopoietic cell transplantation (HCT) and chimeric antigen receptor T-cell (CAR-T) therapy

Safety-and-Immunogenicity-of-the-BNT162b2-mRNA-Covid-19-Vaccine-in-Patients-after-Allogeneic-HCT-or-CD19-based-CAR-T-therapy

For healthcare professionals

This sponsored content is for registered Hong Kong doctors. Log in or register to read it. If you received an access link, open it from your email.

Log inRegister

Related posts

Stylized illustration of a large blue immune cell with surface receptors and yellow nuclei, surrounded by smaller cells.Research · OncologyESCAT v2 adds graded certainty tiers and a resistance scale for molecular targetsAn international ESMO expert panel has revised the 2018 ESCAT framework, restructuring Tier I, Tier II and Tier X, formalising tumour-agnostic gating criteria and adding a four-level scale for resistance biomarkers.8 Nov 2026